Amphastar Pharmaceuticals (AMPH) Current Assets (2013 - 2026)

Amphastar Pharmaceuticals' Current Assets history runs 14 years deep, the most recent figure standing at $633.7 million for Q1 2026.

• In Q1 2026, Current Assets rose 7.78% year-over-year to $633.7 million; the TTM figure through Mar 2026 stood at $633.7 million (up 7.78% YoY), while the FY2025 annual figure was $636.0 million, up 19.09% from the prior year.
• Current Assets was $633.7 million for Q1 2026 at Amphastar Pharmaceuticals, roughly flat from $636.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $639.5 million in Q3 2025 to a low of $364.4 million in Q1 2022.
• Historically, Current Assets has averaged $501.4 million across 5 years, with a median of $534.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Current Assets jumped 41.33% in 2023, then advanced 0.54% in 2024.
• A 5-year view of Current Assets shows it stood at $378.3 million in 2022, then rose by 29.41% to $489.6 million in 2023, then gained by 9.08% to $534.1 million in 2024, then climbed by 19.09% to $636.0 million in 2025, then fell by 0.37% to $633.7 million in 2026.
• The last three Current Assets figures came in at $633.7 million (Q1 2026), $636.0 million (Q4 2025), and $639.5 million (Q3 2025), per Business Quant data.